Suppr超能文献

长期免疫抑制对成人特发性局灶节段性肾小球硬化伴肾病综合征结局的影响。一项合作回顾性研究。

The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study.

作者信息

Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C

机构信息

Division of Nephrology, Ospedale Maggiore, Milan, Italy.

出版信息

Clin Nephrol. 1991 Aug;36(2):53-9.

PMID:1934660
Abstract

In this retrospective study we report the outcome of 59 adults with idiopathic focal-segmental glomerulosclerosis (FSGS) and nephrotic syndrome (NS) treated with corticosteroids and/or immunosuppressive drugs. Twenty-seven patients were initially treated with corticosteroids alone for 9.3 +/- 8 months; nineteen patients received corticosteroids and immunosuppressive agents associated or every other month for 5.5 +/- 4 months; thirteen patients received either azathioprine or cyclophosphamide alone for 25 +/- 27 months. At the end of a mean follow-up of 75 +/- 51 months, 35 patients (60%) were in complete (CR) or partial (PR) remission, 6 (10%) were stable and 18 (30%) had either chronic renal failure (CRF) or end-stage renal failure (ESRF). Out of 36 patients (61%) initially responsive to therapy, 30 (83%) obtained CR, 4 (11%) PR, one (2.7%) developed CRF and one (2.7%) ESRF. Only 10 of the responders (28%) attained remission within 8 weeks of treatment. Out of the 23 (39%) patients originally resistant to therapy, only one (4%) had CR, 6 (26%) remained unchanged, 6 (26%) developed CRF and 10 (43%) ESRF. The presence at initial renal biopsy of interstitial fibrosis was the only feature which could predict a poor renal outcome. These data show that prolonged treatment of FSGS can obtain sustained remission of the disease and improved renal survival in a consistent proportion of adult patients which would be considered refractory to a two-month course with corticosteroids.

摘要

在这项回顾性研究中,我们报告了59例患有特发性局灶节段性肾小球硬化(FSGS)和肾病综合征(NS)的成人患者接受皮质类固醇和/或免疫抑制药物治疗的结果。27例患者最初单独接受皮质类固醇治疗9.3±8个月;19例患者接受皮质类固醇和免疫抑制剂联合治疗或每隔一个月治疗一次,持续5.5±4个月;13例患者单独接受硫唑嘌呤或环磷酰胺治疗25±27个月。在平均随访75±51个月结束时,35例患者(60%)达到完全缓解(CR)或部分缓解(PR),6例(10%)病情稳定,18例(30%)出现慢性肾衰竭(CRF)或终末期肾衰竭(ESRF)。在最初对治疗有反应的36例患者(61%)中,30例(83%)获得CR,4例(11%)获得PR,1例(2.7%)发展为CRF,1例(2.7%)发展为ESRF。只有10例有反应的患者(28%)在治疗8周内达到缓解。在最初对治疗耐药的23例患者(39%)中,只有1例(4%)获得CR,6例(26%)病情未变,6例(26%)发展为CRF,10例(43%)发展为ESRF。初始肾活检时存在间质纤维化是唯一可预测肾脏预后不良的特征。这些数据表明,FSGS的长期治疗可以使相当一部分成年患者获得疾病的持续缓解并改善肾脏存活率,这些患者被认为对两个月的皮质类固醇疗程难治。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验